Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease

Phase 3

Completed

• Conditions: Parkinson's Disease

• Registration Number: NCT01016470
• Lead Sponsor: Catalysis SL

Brief Summary

The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).

Detailed Description

Periodical measures of the clinical features with UPDRS will be done at the beginning, each three months until two years. Each group will be compare to evaluate.

Study Timeline

• Study First Submitted: 2009-09-28
• Study Start: 2009-10
• Study First Submitted QC: 2009-11-18
• Study First Posted: 2009-11-19
• Primary Completion: 2011-05
• Study Completion: 2011-05
• Status Verified: 2012-05
• Last Update Submitted: 2012-05-02
• Last Update Posted: 2012-05-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Patients with clinical of PD, with the criteria of Brain Bank of London with early stage.
• Informed consent.

Exclusion Criteria

• Presence of another disease not well controlled.
• Patient with atypical features.
• Patient with advanced Parkinson's disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment)	one year

Secondary Outcome Measures

Name	Time	Method
Hoehn-Yarh will be done at the beginning, every three months until one year (end of the treatment)	one year
Dosage levodopa will be done at the beginning, every three months until one year (end of the treatment)	one year

Trial Locations

Locations (1)

"Salvador Allende Hospital"; 🇨🇺 Havana City, Havana, Cuba

"Salvador Allende Hospital"

🇨🇺Havana City, Havana, Cuba